The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
about
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutationsMinority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyDynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencingTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanEstimating HIV-1 fitness characteristics from cross-sectional genotype dataPersistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsPotential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsTransmission fitness of drug-resistant HIV revealed in a surveillance system transmission networkIn vivo mutation rates and the landscape of fitness costs of HIV-1.Community HIV-1 drug resistance is associated with transmitted drug resistanceDecreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012The impact of wild-type reversion on transmitted resistance surveillance.HIV-1 diversity after a class switch failure.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Differential persistence of transmitted HIV-1 drug resistance mutation classes.Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsMore effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.Clinical significance of human immunodeficiency virus type 1 replication fitness.Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes.In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.Persistence of HIV-1 transmitted drug resistance mutations.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Soft Selective Sweeps in Evolutionary Rescue.Evolutionary pathways of transmitted drug-resistant HIV-1.The high cost of fidelity.Evolution toward small molecule inhibitor resistance affects native enzyme function and stability, generating acarbose-insensitive cyclodextrin glucanotransferase variants.Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.
P2860
Q28469253-5CE16AFD-5B28-44FA-8197-90666669B106Q28473296-B9038137-2E1C-4B0A-9D90-DC5543AD6D99Q28474783-1CFC545D-2C30-421B-B754-4C9417F44838Q28478656-F0A84B4E-B572-4793-A890-951F7DF7669DQ28486262-4604B9C1-17F7-4545-8A44-410D78F4D7B0Q28537608-626C71DB-DCF0-4EAE-BACF-C70AFA429817Q28544753-1FF4A33F-9DAF-4FD9-A67F-1BC776B90DD3Q28544845-87540FAF-4F7D-4F64-85AD-10AEA735A103Q33299456-3A3D0194-8B10-4197-9E7E-5ECE1B021CDBQ33589187-0A017FC6-FD80-4C03-B148-53DB931AA956Q33589204-8872A1E8-7194-40B9-BD73-D27967FD6901Q33748960-97A8E6B6-7C9E-4C5C-BB87-A9D1F9C23721Q33810988-1E698AB1-2319-46EC-AB70-00C91D1973E9Q34054047-EDF48AB0-9CCA-4E5E-859E-6022F1E9BA40Q34399268-FF4B5C3F-94EF-45CD-99C6-ACAFCDD5D909Q34489422-6FD889E5-F079-4E72-9B12-41BC8604BF33Q34527464-B16254D1-1718-4A66-8C2E-0C1B787E9593Q34615228-C0EB304C-0C59-4442-AEF0-1BA9FF28C632Q34626108-47C58B49-3AC7-4EE1-B87F-1D9E61CD4442Q34677368-2393FC2D-4576-457A-AFC7-29CFF673BD1EQ34937254-0AEDEECA-8DF0-40D6-815B-916A63D5FCD1Q35022802-0D3EEB2E-4822-4A5B-8A1A-195A585A5D1CQ35140323-5813A93A-06F7-44BD-BE83-CC55297669C6Q35237036-E88617DF-0F6E-4BC4-8ACA-C7A91530CFA9Q35473551-AF11B312-26C6-4EFD-833B-DE5AC5FB4032Q36255602-CEC1275B-B3F8-4A97-8026-46015887B785Q36367759-1A1079A1-779C-4223-BB07-EF21F9C720FBQ36610081-47FB81B1-0EB0-4502-98CA-EACCD23881D8Q36673315-1589B382-DEF4-4E88-A1E8-A4C5DD69A4D5Q36969857-17E32003-33A5-4432-8A3D-FC78E8AA0E87Q37091671-5D9F57A2-ACBE-4353-B69D-E0425392695CQ37099813-5FBA39FE-B251-4B89-8504-1F227B373E8FQ37111658-3AC19A34-9FAA-4F30-B217-A68CA5A4658BQ37213028-9F798574-E71F-4DA4-A5CE-4C7CE487F712Q37256719-0CA89BA1-ADFB-458F-B04F-826EFD933E64Q37735450-3839E7FC-6088-422D-A150-30D6096061E3Q37866540-256AC121-13D5-4AE0-A4F4-BE66A89A8B9CQ38158093-1E51A482-252C-4404-B034-43D7EE25031BQ38293433-341D0801-4FBD-4DE5-9E94-1D32162B31A7Q38543385-C5A161C4-7A4F-41B7-B584-14DE13D79FE4
P2860
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The fitness cost of mutations ...... ed by mutational interactions.
@ast
The fitness cost of mutations ...... ed by mutational interactions.
@en
type
label
The fitness cost of mutations ...... ed by mutational interactions.
@ast
The fitness cost of mutations ...... ed by mutational interactions.
@en
prefLabel
The fitness cost of mutations ...... ed by mutational interactions.
@ast
The fitness cost of mutations ...... ed by mutational interactions.
@en
P2860
P356
P1433
P1476
The fitness cost of mutations ...... ed by mutational interactions.
@en
P2093
J Gerardo García-Lerma
Mian-er Cong
P2860
P304
P356
10.1128/JVI.02712-06
P407
P577
2006-12-27T00:00:00Z